The detection of EGFR mutations in ctDNA from NSCLC patients has proved to be complementary to tissue biopsy in clinical practice and is correlated with both the tumor baseline lesion size and response to EGFR TKIs [33,34]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.